Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Arohi Asset Management PTE Ltd.

Arohi Asset Management PTE Ltd. increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 91.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 121,270 shares of the life sciences company's stock after purchasing an additional 58,070 shares during the quarter. Illumina makes up about 4.4% of Arohi Asset Management PTE Ltd.'s portfolio, making the stock its 4th largest holding. Arohi Asset Management PTE Ltd. owned about 0.08% of Illumina worth $16,205,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Keel Point LLC acquired a new stake in Illumina during the 4th quarter worth about $204,000. Ion Asset Management Ltd. grew its stake in Illumina by 10.9% in the 4th quarter. Ion Asset Management Ltd. now owns 800,500 shares of the life sciences company's stock valued at $106,971,000 after purchasing an additional 79,001 shares during the period. Perbak Capital Partners LLP bought a new stake in Illumina in the fourth quarter worth about $1,201,000. Lido Advisors LLC grew its holdings in Illumina by 18.1% during the fourth quarter. Lido Advisors LLC now owns 3,392 shares of the life sciences company's stock valued at $453,000 after purchasing an additional 521 shares during the period. Finally, Northern Trust Corp increased its holdings in Illumina by 26.9% in the 4th quarter. Northern Trust Corp now owns 1,652,935 shares of the life sciences company's stock worth $220,882,000 after acquiring an additional 349,878 shares during the last quarter. Institutional investors own 89.42% of the company's stock.

Illumina Stock Up 0.4 %

Shares of NASDAQ ILMN traded up $0.29 during midday trading on Monday, hitting $78.17. The company's stock had a trading volume of 1,123,593 shares, compared to its average volume of 2,276,174. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The firm has a market capitalization of $12.37 billion, a price-to-earnings ratio of -10.18, a price-to-earnings-growth ratio of 1.60 and a beta of 1.35. The business's fifty day simple moving average is $79.75 and its two-hundred day simple moving average is $114.99. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Barclays reduced their target price on Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a report on Thursday, April 10th. Robert W. Baird lowered their price objective on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a report on Wednesday, March 5th. Guggenheim reduced their price target on Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Piper Sandler upped their price objective on shares of Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Finally, TD Cowen lowered shares of Illumina from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $177.00 to $140.00 in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $137.55.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.